A Pilot Study of Warm & Cold Compress to Reduce Injection Site Erythema

Status Completed

Clinical Trial Summary

Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.

Clinical Trial Description

The most common adverse event associated with this subcutaneously (SC) injected drug is injection site reaction (ISR) including redness and pain.Theoretically, both heat and cold modalities may improve interferon injection tolerance. Warm compress before injection may increase local blood flow and increase rapid systemic absorption, while cold compress afterward may reduce the erythema, edema and pain that often follow SC injections. A trial comparing heat-before and cold-after therapy is warranted to determine the relative effectiveness of these modalities. Intervention: Product: Reusable cold and warm compress. Patients will receive written instructions for microwave heating and freezer cooling of the compress. Warm compress: Pre-heating in microwave oven, per instructions. Apply warm compress for 5 minutes prior to injection. The initial compress temperature will be about 43 degrees Celsius (range 40-46 degrees Celsius) and slowly decline during application. Administer drug soon after removal. Cold compress: Cooling in a freezer as per instructions. Soon after drug injection, apply cold compress for 10 minutes. The initial compress temperature will range 15-18 degrees Celsius. - Timers will be utilized to mark 5-minute and 10-minute treatment intervals - Participants will be encouraged to maintain constant practices with regards to non-steroidal anti-inflammatory drug use during the study Study Objectives: 1. To assess and compare the impact on erythema of two thermal treatments: warm compress prior to PEG injection and cold compress following PEG injection 2. To assess the natural history of PEG-erythema over time. This will be accomplished with 18 weeks of observation in the control group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02490943
Study type	Interventional
Source	Brown, Theodore R., M.D., MPH
Contact
Status	Completed
Phase	N/A
Start date	June 2015
Completion date	April 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04290273` - Characterisation of the Time-course Response of UV-induced Erythema	N/A
Completed	`NCT01659853` - Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea	Phase 3
Completed	`NCT00839462` - Efficacy of Dexpanthenol in Thermic Erythema	Phase 2
Not yet recruiting	`NCT06016361` - Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy	N/A
Completed	`NCT03633877` - Durapore vs. Hy-Tape to Secure The Endotracheal Tube	N/A
Active, not recruiting	`NCT02876107` - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer	Phase 2
Completed	`NCT06369675` - Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design	Phase 1
Completed	`NCT03352323` - An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea	Phase 3
Completed	`NCT06369727` - Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design	Phase 1
Completed	`NCT03041064` - Multiday Beach Study	N/A
Completed	`NCT02832141` - Effect of Thoracic Spine Mobilization on Sympathetic Nervous Systems
Completed	`NCT02131636` - Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea	Phase 3
Terminated	`NCT01597921` - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer	N/A
Completed	`NCT01636765` - Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
Completed	`NCT01124513` - Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI	N/A
Terminated	`NCT03496584` - Effects of Phytonutrients on Vascular Health and Skin in Obese Males	N/A
Completed	`NCT02737592` - A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects	N/A
Completed	`NCT03852563` - A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering	N/A
Completed	`NCT05300542` - Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema	N/A
Completed	`NCT03477825` - Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS — PEG-Thermal

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms